Literature DB >> 4327997

Control of respiratory disease in recruits with types 4 and 7 adenovirus vaccines.

F H Top, B A Dudding, P K Russell, E L Buescher.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1971        PMID： 4327997     DOI： 10.1093/oxfordjournals.aje.a121306

Source DB:  PubMed          Journal:  Am J Epidemiol        ISSN： 0002-9262            Impact factor:   4.897


× No keyword cloud information.
  28 in total

1.  Sublingual administration of an adenovirus serotype 5 (Ad5)-based vaccine confirms Toll-like receptor agonist activity in the oral cavity and elicits improved mucosal and systemic cell-mediated responses against HIV antigens despite preexisting Ad5 immunity.

Authors:  Daniel M Appledorn; Yasser A Aldhamen; Sarah Godbehere; Sergey S Seregin; Andrea Amalfitano
Journal:  Clin Vaccine Immunol       Date:  2010-11-17

2.  Characterization of a permissive epitope insertion site in adenovirus hexon.

Authors:  Michael J McConnell; Xavier Danthinne; Michael J Imperiale
Journal:  J Virol       Date:  2006-06       Impact factor: 5.103

3.  Novel adenovirus vaccine vectors based on the enteric-tropic serotype 41.

Authors:  Franck Lemiale; Hedi Haddada; Gary J Nabel; Douglas E Brough; C Richter King; Jason G D Gall
Journal:  Vaccine       Date:  2006-11-28       Impact factor: 3.641

Review 4.  Immunization today--a review.

Authors:  M I Marks; M Brazeau; R M Shapera
Journal:  Can Med Assoc J       Date:  1973-06-02       Impact factor: 8.262

5.  Enteric immunization with live adenovirus type 21 vaccine. II. Systemic and local immune responses following immunization.

Authors:  R M Scott; B A Dudding; S V Romano; P K Russell
Journal:  Infect Immun       Date:  1972-03       Impact factor: 3.441

6.  The Use of Test-negative Controls to Monitor Vaccine Effectiveness: A Systematic Review of Methodology.

Authors:  Huiying Chua; Shuo Feng; Joseph A Lewnard; Sheena G Sullivan; Christopher C Blyth; Marc Lipsitch; Benjamin J Cowling
Journal:  Epidemiology       Date:  2020-01       Impact factor: 4.822

7.  Cytokine response and survival of mice immunized with an adenovirus expressing Bacillus anthracis protective antigen domain 4.

Authors:  Michael J McConnell; Philip C Hanna; Michael J Imperiale
Journal:  Infect Immun       Date:  2006-02       Impact factor: 3.441

8.  Replication-attenuated Human Adenoviral Type 4 vectors elicit capsid dependent enhanced innate immune responses that are partially dependent upon interactions with the complement system.

Authors:  Zachary C Hartman; Daniel M Appledorn; Delila Serra; Oliver Glass; Todd B Mendelson; Timothy M Clay; Andrea Amalfitano
Journal:  Virology       Date:  2008-02-15       Impact factor: 3.616

9.  Vaccine-preventable adenoviral respiratory illness in US military recruits, 1999-2004.

Authors:  Kevin L Russell; Anthony W Hawksworth; Margaret A K Ryan; Jennifer Strickler; Marina Irvine; Christian J Hansen; Gregory C Gray; Joel C Gaydos
Journal:  Vaccine       Date:  2006-01-24       Impact factor: 3.641

10.  Molecular epidemiology of adenoviruses: global distribution of adenovirus 7 genome types.

Authors:  G Wadell; M K Cooney; A da Costa Linhares; L de Silva; M L Kennett; R Kono; R Gui-Fang; K Lindman; J P Nascimento; B D Schoub
Journal:  J Clin Microbiol       Date:  1985-03       Impact factor: 5.948
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.